DK0754231T3 - Peptidfragment fra G-proteinet fra respiratorisk syncytialvirus, immunogent middel, farmaceutisk præparat, der indeholder det, og fremgangsmåde til fremstilling deraf - Google Patents

Peptidfragment fra G-proteinet fra respiratorisk syncytialvirus, immunogent middel, farmaceutisk præparat, der indeholder det, og fremgangsmåde til fremstilling deraf

Info

Publication number
DK0754231T3
DK0754231T3 DK95916721T DK95916721T DK0754231T3 DK 0754231 T3 DK0754231 T3 DK 0754231T3 DK 95916721 T DK95916721 T DK 95916721T DK 95916721 T DK95916721 T DK 95916721T DK 0754231 T3 DK0754231 T3 DK 0754231T3
Authority
DK
Denmark
Prior art keywords
protein
sequence
immunogenic agent
respiratory syncytial
syncytial virus
Prior art date
Application number
DK95916721T
Other languages
English (en)
Inventor
Hans Binz
Guyen Ngoc Thien N
Thierry Baussant
Michel Trudel
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Application granted granted Critical
Publication of DK0754231T3 publication Critical patent/DK0754231T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK95916721T 1994-04-06 1995-04-06 Peptidfragment fra G-proteinet fra respiratorisk syncytialvirus, immunogent middel, farmaceutisk præparat, der indeholder det, og fremgangsmåde til fremstilling deraf DK0754231T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9404009A FR2718452B1 (fr) 1994-04-06 1994-04-06 Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.

Publications (1)

Publication Number Publication Date
DK0754231T3 true DK0754231T3 (da) 2006-10-23

Family

ID=9461767

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95916721T DK0754231T3 (da) 1994-04-06 1995-04-06 Peptidfragment fra G-proteinet fra respiratorisk syncytialvirus, immunogent middel, farmaceutisk præparat, der indeholder det, og fremgangsmåde til fremstilling deraf

Country Status (14)

Country Link
US (5) US6113911A (da)
EP (2) EP0754231B1 (da)
JP (2) JP3883569B2 (da)
AT (1) ATE331031T1 (da)
AU (1) AU708856B2 (da)
BR (1) BR1100321A (da)
CA (2) CA2635998A1 (da)
DE (1) DE69535074T2 (da)
DK (1) DK0754231T3 (da)
ES (1) ES2268691T3 (da)
FR (1) FR2718452B1 (da)
NZ (2) NZ284500A (da)
PT (1) PT754231E (da)
WO (1) WO1995027787A1 (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
ATE178906T1 (de) * 1994-08-25 1999-04-15 Stichting Inst Dierhouderij Antigene peptide abgeleitet vom g-protein des rsv (respiratorisches synzytialvirus) für die typen- und subtypen spezifische diagnose einer rsv- infektionen
FR2726472B1 (fr) 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
FR2748476B1 (fr) * 1996-05-07 1998-08-14 Pf Medicament Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant
AUPO026596A0 (en) * 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
FR2766192B1 (fr) * 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
US6451987B1 (en) * 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
FR2790959B1 (fr) * 1999-03-15 2003-06-27 Pf Medicament Utilisation de fractions membranaires bacteriennes a effet adjuvant, leurs procedes de preparation et composition pharmaceutique les contenant
EP1174506A1 (en) 2000-06-28 2002-01-23 Stichting Dienst Landbouwkundig Onderzoek C-terminal Erns peptide and analogues thereof
EP1334119B2 (en) † 2000-10-18 2018-11-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Compositions and methods for modulating rsv infection and immunity
FR2819810B1 (fr) * 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
FR2827605B1 (fr) * 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
PL1664108T3 (pl) * 2003-08-21 2010-03-31 Novo Nordisk As Rozdzielanie polipeptydów zawierających racemizowany aminokwas
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US20100040606A1 (en) * 2006-03-06 2010-02-18 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
FR2899902B1 (fr) * 2006-04-18 2012-01-27 Agronomique Inst Nat Rech Proteines de fusion proteine n d'un virus de la famille des paramyxoviridae-proteine d'interet et leurs utilisations pour la vaccination et la vectorisation intra-cellulaire.
US8647349B2 (en) 2006-10-18 2014-02-11 Hologic, Inc. Systems for performing gynecological procedures with mechanical distension
US8025656B2 (en) 2006-11-07 2011-09-27 Hologic, Inc. Methods, systems and devices for performing gynecological procedures
US9392935B2 (en) 2006-11-07 2016-07-19 Hologic, Inc. Methods for performing a medical procedure
CA2678628A1 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
US9259233B2 (en) 2007-04-06 2016-02-16 Hologic, Inc. Method and device for distending a gynecological cavity
US8951274B2 (en) 2007-04-06 2015-02-10 Hologic, Inc. Methods of high rate, low profile tissue removal
US9095366B2 (en) 2007-04-06 2015-08-04 Hologic, Inc. Tissue cutter with differential hardness
US8574253B2 (en) 2007-04-06 2013-11-05 Hologic, Inc. Method, system and device for tissue removal
DE08786222T1 (de) * 2007-07-31 2010-11-25 Affibody Ab Neue albuminbindende zusammensetzungen, verfahren und anwendungen
KR100938105B1 (ko) 2007-09-21 2010-01-21 이화여자대학교 산학협력단 호흡기 신시치아 바이러스 백신
US8563002B2 (en) 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
KR20110045008A (ko) * 2008-07-18 2011-05-03 아이디 바이오메디컬 코포레이션 오브 퀘벡 키메라 호흡기 세포융합 바이러스 폴리펩티드 항원
NZ591768A (en) 2008-09-18 2012-11-30 Novartis Ag Vaccine adjuvant combinations
US11903602B2 (en) 2009-04-29 2024-02-20 Hologic, Inc. Uterine fibroid tissue removal device
PL2445526T3 (pl) 2009-06-24 2017-08-31 Glaxosmithkline Biologicals S.A. Rekombinowane antygeny rsv
SG176807A1 (en) 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
EP4183412B1 (en) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Rsv f protein compositions and methods for making same
US8846056B2 (en) 2009-08-04 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control Anti-RSV immunogens and methods of immunization
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
CN106008716B (zh) 2010-07-07 2019-08-13 人工细胞科技公司 呼吸道合胞病毒抗原组合物和方法
JP2013538217A (ja) 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着
ES2630029T3 (es) 2010-12-14 2017-08-17 Glaxosmithkline Biologicals Sa Análisis de citometría de flujo de materiales adsorbidos en sales metálicas
CN103533954B (zh) 2011-03-02 2015-09-09 诺华股份有限公司 含较低剂量的抗原和/或佐剂的联合疫苗
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
US9463236B2 (en) 2011-08-29 2016-10-11 Tokushima University RSV mucosal vaccine
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
RU2014140336A (ru) 2012-03-07 2016-04-27 Новартис Аг Иммунологически полезные соли аргинина
CA2866406A1 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
SI2879702T1 (sl) 2012-08-01 2020-02-28 Bavarian Nordic A/S Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV)
KR101705603B1 (ko) * 2015-03-19 2017-02-13 을지대학교 산학협력단 엔테로박테리아세아 유래 세포 투과 단백질 및 이의 용도
BR112018016648A2 (pt) * 2016-02-16 2018-12-26 The University Of Queensland peptídeos alfa-conotoxina
EP3765516A2 (en) * 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005823A1 (en) * 1987-12-23 1989-06-29 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
DE3828666A1 (de) * 1988-08-24 1990-03-01 Behringwerke Ag Expression funktionsfaehiger homologer und heterologer proteine auf der aeusseren membran von e.coli und anderen gramnegativen bakterien
WO1992004375A1 (en) * 1990-08-31 1992-03-19 The Upjohn Company Hrsv vaccine
SE9101433D0 (sv) * 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.

Also Published As

Publication number Publication date
US6113911A (en) 2000-09-05
JP3883569B2 (ja) 2007-02-21
ES2268691T3 (es) 2007-03-16
PT754231E (pt) 2006-11-30
EP1111053A2 (fr) 2001-06-27
DE69535074D1 (de) 2006-08-03
BR1100321A (pt) 2000-03-21
NZ284500A (en) 1998-04-27
CA2187083A1 (fr) 1995-10-19
US7220545B2 (en) 2007-05-22
US20050250933A1 (en) 2005-11-10
ATE331031T1 (de) 2006-07-15
US6537556B1 (en) 2003-03-25
CA2635998A1 (fr) 1995-10-19
US6410030B1 (en) 2002-06-25
EP1111053A3 (fr) 2001-08-08
JPH09511404A (ja) 1997-11-18
AU2310995A (en) 1995-10-30
DE69535074T2 (de) 2007-06-28
EP0754231B1 (fr) 2006-06-21
JP4180590B2 (ja) 2008-11-12
AU708856B2 (en) 1999-08-12
US6616930B2 (en) 2003-09-09
EP0754231A1 (fr) 1997-01-22
US20030064078A1 (en) 2003-04-03
WO1995027787A1 (fr) 1995-10-19
JP2006020637A (ja) 2006-01-26
CA2187083C (fr) 2011-06-07
FR2718452B1 (fr) 1996-06-28
FR2718452A1 (fr) 1995-10-13
NZ329833A (en) 2000-02-28

Similar Documents

Publication Publication Date Title
AU2310995A (en) Peptide fragment of the respiratory syncytial virus protein g, immunogenic agent, pharmaceutical composition containing it and preparation process
TR199802789T2 (xx) Eksendin analoglar� bunlar�n �retimi i�in y�ntemler ve bunlar� i�eren farmas�tik m�stahzarlar.
DK0662827T3 (da) Terapeutiske og diagnostiske fremgangsmåder og sammensætninger baseret på Notch-proteiner og nucleinsyrer
RU93046317A (ru) Хиндроитиназа, способ ее получения и содержание ее фармацевтические композиции
WO1998004702A3 (en) Proteins, in particular membrane proteins, of helicobacter pylori, their preparation and use
DK0506574T3 (da) Protein med aktivitet af cytokintype, rekombinant-DNA, der koder for dette protein, celler og transformerede mikroorganismer
DK0567100T3 (da) Respiratorisk syncytial virus (RSV)-mutant og farmaceutisk præparat indeholdende en sådan mutant
IL82364A0 (en) Recombinant alveolar surfactant protein,its production and purification and pharmaceutical compositions containing it
DE3777845D1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
DK0791063T3 (da) Bærerprotein med adjuvansvirkning, immunogent kompleks omfattende det, fremgangsmåde til fremstilling deraf, nukleotidsekvens og vaccine
ATE397662T1 (de) Neues polypeptid, dafür kodierende dna und deren verwendungen
IL88378A (en) Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
WO2001055353A3 (en) Recombinant attenuation of prrsv
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
CA2142712A1 (en) Bordetella bronchiseptica vaccine
RU95101042A (ru) Рекомбинантный полипептид, антисыворотки, фармацевтическая композиция, способ ингибирования транспорта катионных аминокислот, способ ингибирования продукции окиси азота, способ лечения
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
PL355852A1 (en) Fragments of virus protein vp2 or 3 of the polyoma virus, used for transporting active ingredients
EP0367641A3 (en) Lymphokines, dna sequences encoding these lymphokines and pharmaceutical compositions containing these lymphokines
EP0723016A3 (en) Leukocyte activation factor
DE3162674D1 (en) A purified polypeptide, a process for its preparation, its use and pharmaceutical compositions containing it
SE9402253D0 (sv) Process
IL81886A (en) Bacillus thuringiensis insecticidal proteinaceous substance,dna encoding it,its preparation and its use
KR920700224A (ko) 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제
WO1992001794A3 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung